CagriSema: The Complete 2026 Guide (Mechanism, Dosing, Cost)

CagriSema at a glance:

• Drug class: Combination amylin analog (cagrilintide) + GLP-1 agonist (semaglutide)
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection (combined formulation)
• Typical frequency: once weekly
• Half-life: approximately 7 days for both components
• Receptor target: amylin and GLP-1 receptors

Most people land on a CagriSema page because they're weighing it against another option, trying to manage side effects, or trying to figure out if it's worth the money. We try to answer all three honestly here. The headline: Phase 2 trials showed mean weight loss around 17% at 32 weeks. REDEFINE phase 3 reported 22.7% weight loss at 68 weeks.

What is CagriSema?

CagriSema combines cagrilintide (a long-acting amylin analog) with semaglutide. The amylin pathway adds to GLP-1's appetite suppression through a separate mechanism, with the goal of greater total weight loss.

CagriSema is manufactured by Novo Nordisk. CagriSema is not currently approved by the FDA for general human use. Available evidence comes from ongoing clinical trials. We do not endorse self-administration of unapproved compounds.

The drug class combination amylin analog (cagrilintide) + glp-1 agonist (semaglutide) works by acting at the amylin and GLP-1 receptors. Here's what to expect.

How CagriSema Works in the Body

CagriSema combines cagrilintide (a long-acting amylin analog) with semaglutide. The amylin pathway adds to GLP-1's appetite suppression through a separate mechanism, with the goal of greater total weight loss. The receptor target — amylin and GLP-1 receptors — drives the downstream effects users care about: phase 2 trials showed mean weight loss around 17% at 32 weeks. redefine phase 3 reported 22.7% weight loss at 68 weeks.

The pharmacokinetics matter for daily use. CagriSema has a half-life of approximately 7 days for both components, which determines how often it is dosed. The standard route of administration is subcutaneous injection (combined formulation), and the typical schedule is once weekly.

For more detail on the underlying biology, see our breakdown of how CagriSema works.

Who Uses CagriSema?

CagriSema is most relevant for people whose situation maps to its approved indications: none yet — phase 3 trials ongoing for obesity.

People who should avoid CagriSema include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of CagriSema include:

• nausea
• diarrhea
• vomiting
• decreased appetite

Serious risks — uncommon but worth knowing — include:

• class-typical incretin risks pending long-term data

We have a more detailed breakdown in our CagriSema side-effects guide.

CagriSema vs Alternatives

Comparable approved alternatives are Wegovy and Zepbound. Novo expects a regulatory filing for CagriSema after the phase 3 program completes. If you are weighing CagriSema against another option, our comparison pages include CagriSema Side Effects in 2026: Real Reports, Real Solutions, What Results Should You Expect from CagriSema? A Practical Guide, The Real CagriSema Price Tag in 2026 — With and Without Insurance.

Bottom Line

Treat CagriSema as one tool among several. The most successful users we see treat it as part of a structured approach, not a standalone fix. Phase 2 and 3 data show meaningful benefit, with phase 3 confirmation pending in some cases. If you are considering CagriSema, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• CagriSema Side Effects in 2026: Real Reports, Real Solutions
• What Results Should You Expect from CagriSema? A Practical Guide
• The Real CagriSema Price Tag in 2026 — With and Without Insurance
• Using CagriSema for Weight Loss: A Practical Patient Guide
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.
• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.